Guidelines for Antiretroviral Therapy of HIV infection in Infants and Children: Towards universal access References 74.
Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. JInfect Dis. 2005Dec 1; 192(11):1921-30.
75.
Ena J, Amador C, Benito C, Fenoll V, Pasquau F. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients. Int JSTD AIDS. 2003 Nov; 14(11):776-81.
76.
Keiser P, Nassar N, White C, Koen G, Moreno S. Comparison of nevirapine-and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study. HIV Clin Trials. 2002Jul-Aug; 3(4):296-303.
77.
Keiser P, Nassar N, Yazdani B, Armas L, Moreno S. Comparison of efficacy of efavirenz and nevirapine: lessons learned for cohort analysis in light of the 2NN Study. HIV Clin Trials. 2003 Sep-Oct; 4(5):358-60.
78.
Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIVNAT Cohort, Thailand, 1996-2001. Aids. 2003 Oct 17; 17(15):2191-9.
79.
Martin-Carbonero L, Nunez M,Gonzalez-LahozJ,Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials. 2003 Mar-Apr; 4(2):115-20.
80.
Moyle GJ. NNRTI choice: has 2NN changed our practice? AIDS Read. 2003 Jul; 13(7):325-8.
81.
van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study. Lancet. 2004Apr 17; 363(9417):1253-63.
82.
Teglas JP, Quartier P, Treluyer JM, Burgard M, Gregoire V, Blanche S. Tolerance of efavirenz in children. Aids. 2001 Jan 26; 15(2):241-3.
83.
Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). Aids. 2001 Oct 19; 15(15):1951-7.
84.
Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, Berrebi A, Benifla JL, Burgard M, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. Jama. 2001 Apr 25; 285(16):2083-93.
85.
Bulterys M, Weidle PJ, Abrams EJ, Fowler MG. Combination antiretroviral therapy in African nursing mothers and drug exposure in their infants: new pharmacokinetic and virologic findings. JInfect Dis. 2005Sep 1; 192(5):709-12.
86.
McComsey GA, Leonard E. Metabolic complications of HIV therapy in children. Aids. 2004Sep 3; 18(13):1753-68.
94